The life sciences industry has welcomed the latest Brexit position paper published by the UK’s Department for Existing the European Union.
Both the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of Continuity in the availability of goods for the EU and the UK.
The paper outlines a range of principles “to ensure that goods which are placed on the market before exit day can continue to be sold in the UK and EU”.
This includes “avoiding unnecessary duplication of compliance activities that have been undertaken by businesses prior to exit” and facilitating “the continued oversight of products to ensure the necessary action can be taken for non-compliant or unsafe goods”.
Dr Virginia Acha, Executive Director of The ABPI and Steve Bates, CEO, BIA said: “ABPI and BIA welcome the publication by UK Government of its position paper on ‘Continuity in the availability of goods for the EU and UK’ in support of its negotiations with the EU.
“We welcome this paper’s pragmatic approach, which provides a constructive starting point for arrangements that aim to minimise disruption to vital safety and monitoring processes for medicines and avoid any negative impact to medicines supply.
“As soon as the negotiations resume, we urge the EU and UK to discuss this issue with Europe’s patients front of mind.”